Zacks Investment Research on MSN5d
Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...
Insider Monkey14d
Why GSK plc (GSK) Is One of the Best Vaccine Stocks to Buy According to Hedge Funds
In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best vaccine stocks to buy now. On February 24, CNBC reported that President Trump declared that ...
Business Insider21d
GlaxoSmithKline (GSK) Gets a Buy from Bernstein
Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90. The company’s shares opened today at p1,443. ...
moneycontrol.com22d
GSK Pharma shares jump 15%, extend gains to 2nd straight day after strong Q3 results
The shares of GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) jumped over 15 percent to trade at Rs 2,684 apiece on February 18, extending gains for the second straight session after releasing ...
Mint22d
GlaxoSmithKline share price extends post-Q3 results rally. Jumps 36% in two days
GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the ...
Seeking Alpha22d
GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'
GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...
BioPharma Dive23d
GSK’s 5-in-1 meningococcal shot wins FDA approval
The Food and Drug Administration on Friday gave a green light to a new meningococcal vaccine from GSK. Dubbed Penmenvy, the “5-in-1” shot is approved for people aged 10 through 25 years old and ...
cnbctv1823d
GSK Pharma shares surge 20% in a weak market; Here's why
Shares of GlaxoSmithKline Pharmaceuticals Ltd. are trading with gains of 20% on Monday, February 17, bucking in trend in a market where most Nifty 50 constituents are trading with losses. GSK Pharma ...
Mint23d
GlaxoSmithKline Pharmaceuticals shares hit 20% upper circuit as profit jumps fivefold in Q3FY25
Commenting on the results, Bhushan Akshikar, MD of GlaxoSmithKline Pharmaceuticals, highlighted the company’s strategic initiatives in strengthening its market presence and enhancing access to ...
Business Standard23d
GlaxoSmithKline hits 20% upper circuit on posting 400% jump in Q3 PAT
GlaxoSmithKline Pharmaceuticals shares hit 20 per cent upper circuit in trade on BSE at Rs 2,421.3 per share. The buying on the counter came after the company posted its Q3 results. Around 9:52 AM, ...
This is Money23d
GSK gets meningitis vaccine green light from US FDA
US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake of Donald Trump's election for a second term as President. The Food ...
Yahoo Finance24d
PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY
Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...